Table 6.
Variable | AL | ASAQ-FDC | DP | |||
---|---|---|---|---|---|---|
Day 3 PPR (95 % CI) | Maximum predicted riska | Day 3 PPR (95 % CI) | Maximum predicted riska | Day 3 PPR (95 % CI) | Maximum predicted riska | |
Age category | ||||||
<1 year | 0.79 (0.00–1.67) | 6.50 | 0.67 (0.00–2.00) | 7.69 | 0.68 (0.00–1.45) | 6.00 |
1 to <5 years | 0.54 (0.28–0.79) | 4.30 | 0.70 (0.19–1.21) | 6.00 | 0.83 (0.00–1.65) | 6.35 |
5 to <12 years | 0.69 (0.26–1.11) | 6.00 | 0.32 (0.00–0.76) | 4.11 | 0.70 (0.07–1.34) | 6.00 |
≥12 years | 0.49 (0.11–0.88) | 4.76 | 0.13 (0.00–0.40) | 4.00 | 0.48 (0.00–1.06) | 5.66 |
Transmission | ||||||
High | 0.20 (0.03–0.37) | 4.00 | 0.27 (0.06–0.48) | 4.00 | 0.05 (0.00–0.15) | 2.00 |
Low/moderate | 0.79 (0.43–1.15) | 6.00 | 0.65 (0.09–1.22) | 6.00 | 1.28 (0.27–2.29) | 8.00 |
Parasitaemia (x 1,000 parasites/μl) | ||||||
<10 | 0.39 (0.18–0.60) | 4.00 | 0.43 (0.00–0.91) | 4.92 | 0.87 (0.00–1.81) | 7.02 |
10 to <50 | 0.58 (0.30–0.86) | 4.62 | 0.35 (0.00–0.72) | 4.00 | 0.54 (0.01–1.08) | 5.77 |
50 to <100 | 0.81 (0.32–1.30) | 6.00 | 1.01 (0.20–1.83) | 7.02 | 0.86 (0.00–1.85) | 7.14 |
≥100 | 1.04 (0.35–1.74) | 6.67 | 1.12 (0.00–2.25) | 8.00 | 1.15 (0.13–2.17) | 8.00 |
Study sample size | ||||||
<50 | 1.02 (0.12–1.92) | 10.34 | 0.78 (0.00–2.00) | 10.71 | 0.00 (0.00–7.71) | 20.68 |
50 to <100 | 0.72 (0.30–1.13) | 6.00 | 0.55 (0.00–1.53) | 6.00 | 0.25 (0.00–0.50) | 4.00 |
100 to <200 | 0.90 (0.34–1.45) | 4.62 | 0.88 (0.08–1.68) | 5.00 | 1.43 (0.00–3.03) | 7.01 |
≥200 | 0.25 (0.05–0.45) | 1.75 | 0.18 (0.02–0.35) | 1.50 | 0.70 (0.00–1.73) | 4.00 |
Overall | 0.58 (0.34–0.82) | 4.41 | 0.54 (0.14–0.94) | 5.08 | 0.77 (0.11–1.42) | 6.00 |
aThe maximum predicted risk is the day 3 PPR which could be observed assuming the worst case day 3 PPR, that is, the upper limit of day 3 PPR 95 % CI. For calculating the maximum predicted risk for age, transmission and parasitaemia, a minimum study sample size of 50 in a study was assumed. AL, artemether-lumefantrine; ASAQ-FDC, fixed dose combination; DP, dihydroartemisinin-piperaquine; PPR, parasite positivity rate